Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases.
Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn's disease. It is a group of chronic disorders characterized by inflammation of the gastrointestinal track with unknown etiology. Currently applied biomarkers include CRP, ESR, pANCA, ASCA, and fecal calprotectin. The etiopathogenesis of IBD is multifactorial. In patients with IBD in inflamed alimentary tract mucosa the number of recruited monocytes and activated macrophages which are source of cytokines. In IBD, the exacerbation is accompanied by thrombocytosis. Platelets play a crucial role in the hemostasis and inflammatory response. Selectins, which regulates the hemostasis and inflammatory response, stimulates the secretion of many inflammatory mediators such as β-thromboglobuline, CD40L, fibrinogen, IL-1β, platelet factor-4. In the course of IBD the following changes are observed: an increase in the number of platelets (reactive thrombocytosis), PDW and PCT, reduction in MPV, increased production and excretion of granular content products (P-selectin, GP53, β-TG, PF-4, vWF, fibrinolytic inhibitors).
Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Poland.
Joanna
J
Matowicka-Karna
D015415:Biomarkers; D001777:Blood Coagulation; D001792:Blood Platelets / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D006487:Hemostasis; D006801:Humans; D007249:Inflammation / Q000097:blood; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors